AG
CYTK icon

Artal Group’s Cytokinetics CYTK Stock Holding History

Artal Group’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-494,421
Closed -$26.8M – 24
2024
Q2 		$26.8M Sell
494,421
-12,163
-2% -$734K 0.68% 18
2024
Q1 		$35.5M Sell
506,584
-707,700
-58% -$54.7M 0.9% 17
2023
Q4 		$101M Sell
1,214,284
-304,547
-20% -$11M 3.37% 4
2023
Q3 		$44.7M Buy
1,518,831
+102,800
+7% +$3.42M 1.92% 10
2023
Q2 		$46.2M Buy
1,416,031
+49,008
+4% +$1.81M 1.43% 13
2023
Q1 		$48.1M Buy
1,367,023
+367,023
+37% +$15M 2.86% 9
2022
Q4 		$45.8M Hold
1,000,000
– – 2.56% 12
2022
Q3 		$48.5M Sell
1,000,000
-275,000
-22% -$13.2M 2.07% 15
2022
Q2 		$50.1M Buy
1,275,000
+275,000
+28% +$11.1M 2.68% 10
2022
Q1 		$36.8M Hold
1,000,000
– – 1.54% 17
2021
Q4 		$45.6M Sell
1,000,000
-300,000
-23% -$11.6M 1.24% 22
2021
Q3 		$46.5M Buy
1,300,000
+800,000
+160% +$23.6M 1.04% 24
2021
Q2 		$9.89M Buy
+500,000
New +$11.7M 0.2% 89
2021
Q1 		– Sell
-500,000
Closed -$10.4M – 156
2020
Q4 		$10.4M Buy
+500,000
New +$9.14M 0.22% 87

Other funds holding CYTK

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Artal Group's CYTK Position: Q3 2024 in Review

Artal Group sold out of Cytokinetics (CYTK) in Q3 2024, closing a stake of 494,421 shares — an estimated $26.8M sold.

Artal Group first reported a position in CYTK in Q4 2020 and held it in 14 quarters. The position peaked at $101M in Q4 2023. 347 funds tracked by Wall St. Rank hold CYTK as of Q3 2024.

  • Artal Group reported no remaining Cytokinetics position as of Q3 2024 after selling out during the quarter.
  • Artal Group sold 494,421 Cytokinetics shares in Q3 2024, an estimated $26.8M.
  • Artal Group first reported a position in Cytokinetics in Q4 2020 and held it in 14 quarters.
  • Artal Group's Cytokinetics position peaked at $101M in Q4 2023.
  • 347 funds tracked by Wall St. Rank held Cytokinetics as of Q3 2024.

Based on Artal Group's 13F filing for Q3 2024, filed 13 Nov 2024.